84 microarray experimental samples list

Array ID Sample Name Before and after pair (yes or no), and other comments

svcc98.2 NORWAY 7-BE yes

svcc63.2 NORWAY 7-AF yes

svcc78.2 NORWAY 10-BE yes

svcc77.2 NORWAY 10-AF yes

svcc122.2 NORWAY 11 no, no after

svcc68.2 NORWAY 19 no, no after

svcc53.2 NORWAY 12-BE yes

svcc97.2 NORWAY 12-AF yes

svcc81.2 NORWAY 14-BE yes

svcc52.2 NORWAY 14-AF yes

svcc106.2 NORWAY 15-BE yes

svcc64.2 NORWAY 15-AF yes

svcc108.2 NORWAY 16 no, no after

svcc88.2 NORWAY 17 no, no after

svcc134.2 NORWAY 18-BE yes

svcc112.2 NORWAY 18-AF yes

svcc89.2 NORWAY 26-BE yes

svcc91.2 NORWAY 26-AF yes

svcc111.2 NORWAY 27-BE yes

svcc109.2 NORWAY 27-AF yes

svcc1077.2 NEW YORK 1 no

svcc132.2 NEW YORK 2 no

svcc61.2 STANFORD 14 no

svcc137.2 STANFORD 16 no

svcc119.2 STANFORD 17 no

svcc96.2 STANFORD 2-P primary tumor, paired with a metastasis

svcc113.2 STANFORD 2-LN lymph node metastasis from tumor Stanford 2

svcc93.2 NORWAY 39-BE yes

svcc135.2 NORWAY 39-AF yes

svcc107.2 NORWAY 41-BE yes

svcc125.2 NORWAY 41-AF yes

svcc76.2 NORWAY 47-BE yes

svcc79.2 NORWAY 47-AF yes

svcc92.2 NORWAY 48-BE yes

svcc103.2 NORWAY 48-AF yes

svcc99.2 STANFORD 23 no

svcc100.2 STANFORD 24 no

svcc131.2 NORWAY 53-BE yes

svcc58.2 NORWAY 53-AF yes

svcc87.2 NORWAY 56 no, no after

svcc51.2 NORWAY 57 no, no after

svcc118.2 STANFORD 35 no

svcc117.2 STANFORD 37-FA no

svcc115.2 STANFORD 38-P primary tumor, paired with a metastasis

svcc116.2 STANFORD 38-LN lymph node metastasis from tumor Stanford 38

svcc83.2 NORWAY 61-BE yes

svcc66.2 NORWAY 61-AF yes

svcc123.2 NORWAY 65 no, no after

svcc104.2 NORWAY 100-BE yes

svcc86.2 NORWAY 100-AF yes

svcc84.2 NORWAY 101-BE yes

svcc85.2 NORWAY 101-AF yes

svcc101.2 NORWAY 102-BE yes

svcc82.2 NORWAY 102-AF yes

svcc120.2 NORWAY 104-BE yes

svcc65.2 NORWAY 104-AF yes

svcc130.2 NEW YORK 3 no

svcc105.2 NORWAY 109-BE yes

svcc121.2 NORWAY 109-AF yes

svcc55.2 NORWAY 111 no, no after

svcc124.2 NORWAY 112-BE yes

svcc126.2 NORWAY 112-AF yes

svcc70.2 NORMAL 1 Normal Breast 1 (6 pooled whole nomal breasts specimens)

svcc127.2 NORMAL 2 Normal Breast 2 (2 pooled whole nomral breast specimens)

svcc18.2 NORMAL 3 Norway Normal Breast 1 (a sample from a single individual)

svcc128.2 BT-474 cell line; luminal epithelial, ERBB2 positive

svcc69.2 BT-549 cell line; breast derived

svcc500.2 HMEC+IFNa cell line; HMEC-C isolate, basal epithelial cell line plus IFNa

svcc94.2 HMEC-C cell line; HMEC-C isolate, basal epithelial cell line untreated

svcc47.2 HMEC-C CON cell line; HMEC-C isolate, basal epithelial cell line after 2 days at 100% confluence

svcc41.2 HMVEC cell line; human dermal microvacsular endothelial cells

svcc110.2 Hs578T cell line; breast carcinosarcoma derived

svcc42.2 HUVEC cell line; human umbilical vein derived endothelial cell line

svcc1299.2 MCF7 cell line; luminal epithelial, estrogen receptor positive

svcc73.2 MDA-MB-231 cell line; breast tissue derived cell line

svcc72.2 MOLT4 cell line; t-cell leukemia derived

svcc67.2 NB4+ATRA cell line; neutrophil-like after Retinoic Acid induced differentiation (72 hours)

svcc54.2 RPMI-8226 cell line; b-cell like (derived from a multiple myeloma)

svcc15.2 SK-BR-3 cell line; luminal epithelial, ERBB2 positive

svcc74.2 SW872 cell line; liposacroma derived cell line

svcc71.2 T47D cell line; luminal epithelial, estrogen receptor positive

svcc38.2 184A1 cell line; basal epithelial, immortal derivative of 184Aa

svcc17.2 184Aa cell line; basal epithelial, a second HMEC isolate unrelated to HMEC-C

svcc40.2 184B5 cell line; basal epithelial, immortal derivative of 184Aa

Last Updated on 05/04/2000
By Charles M. Perou
Email: perou@genome.stanford.edu

Array ID	Sample Name	Before and after pair (yes or no), and other comments
svcc98.2	NORWAY 7-BE	yes
svcc63.2	NORWAY 7-AF	yes
svcc78.2	NORWAY 10-BE	yes
svcc77.2	NORWAY 10-AF	yes
svcc122.2	NORWAY 11	no, no after
svcc68.2	NORWAY 19	no, no after
svcc53.2	NORWAY 12-BE	yes
svcc97.2	NORWAY 12-AF	yes
svcc81.2	NORWAY 14-BE	yes
svcc52.2	NORWAY 14-AF	yes
svcc106.2	NORWAY 15-BE	yes
svcc64.2	NORWAY 15-AF	yes
svcc108.2	NORWAY 16	no, no after
svcc88.2	NORWAY 17	no, no after
svcc134.2	NORWAY 18-BE	yes
svcc112.2	NORWAY 18-AF	yes
svcc89.2	NORWAY 26-BE	yes
svcc91.2	NORWAY 26-AF	yes
svcc111.2	NORWAY 27-BE	yes
svcc109.2	NORWAY 27-AF	yes
svcc1077.2	NEW YORK 1	no
svcc132.2	NEW YORK 2	no
svcc61.2	STANFORD 14	no
svcc137.2	STANFORD 16	no
svcc119.2	STANFORD 17	no
svcc96.2	STANFORD 2-P	primary tumor, paired with a metastasis
svcc113.2	STANFORD 2-LN	lymph node metastasis from tumor Stanford 2
svcc93.2	NORWAY 39-BE	yes
svcc135.2	NORWAY 39-AF	yes
svcc107.2	NORWAY 41-BE	yes
svcc125.2	NORWAY 41-AF	yes
svcc76.2	NORWAY 47-BE	yes
svcc79.2	NORWAY 47-AF	yes
svcc92.2	NORWAY 48-BE	yes
svcc103.2	NORWAY 48-AF	yes
svcc99.2	STANFORD 23	no
svcc100.2	STANFORD 24	no
svcc131.2	NORWAY 53-BE	yes
svcc58.2	NORWAY 53-AF	yes
svcc87.2	NORWAY 56	no, no after
svcc51.2	NORWAY 57	no, no after
svcc118.2	STANFORD 35	no
svcc117.2	STANFORD 37-FA	no
svcc115.2	STANFORD 38-P	primary tumor, paired with a metastasis
svcc116.2	STANFORD 38-LN	lymph node metastasis from tumor Stanford 38
svcc83.2	NORWAY 61-BE	yes
svcc66.2	NORWAY 61-AF	yes
svcc123.2	NORWAY 65	no, no after
svcc104.2	NORWAY 100-BE	yes
svcc86.2	NORWAY 100-AF	yes
svcc84.2	NORWAY 101-BE	yes
svcc85.2	NORWAY 101-AF	yes
svcc101.2	NORWAY 102-BE	yes
svcc82.2	NORWAY 102-AF	yes
svcc120.2	NORWAY 104-BE	yes
svcc65.2	NORWAY 104-AF	yes
svcc130.2	NEW YORK 3	no
svcc105.2	NORWAY 109-BE	yes
svcc121.2	NORWAY 109-AF	yes
svcc55.2	NORWAY 111	no, no after
svcc124.2	NORWAY 112-BE	yes
svcc126.2	NORWAY 112-AF	yes
svcc70.2	NORMAL 1	Normal Breast 1 (6 pooled whole nomal breasts specimens)
svcc127.2	NORMAL 2	Normal Breast 2 (2 pooled whole nomral breast specimens)
svcc18.2	NORMAL 3	Norway Normal Breast 1 (a sample from a single individual)
svcc128.2	BT-474	cell line; luminal epithelial, ERBB2 positive
svcc69.2	BT-549	cell line; breast derived
svcc500.2	HMEC+IFNa	cell line; HMEC-C isolate, basal epithelial cell line plus IFNa
svcc94.2	HMEC-C	cell line; HMEC-C isolate, basal epithelial cell line untreated
svcc47.2	HMEC-C CON	cell line; HMEC-C isolate, basal epithelial cell line after 2 days at 100% confluence
svcc41.2	HMVEC	cell line; human dermal microvacsular endothelial cells
svcc110.2	Hs578T	cell line; breast carcinosarcoma derived
svcc42.2	HUVEC	cell line; human umbilical vein derived endothelial cell line
svcc1299.2	MCF7	cell line; luminal epithelial, estrogen receptor positive
svcc73.2	MDA-MB-231	cell line; breast tissue derived cell line
svcc72.2	MOLT4	cell line; t-cell leukemia derived
svcc67.2	NB4+ATRA	cell line; neutrophil-like after Retinoic Acid induced differentiation (72 hours)
svcc54.2	RPMI-8226	cell line; b-cell like (derived from a multiple myeloma)
svcc15.2	SK-BR-3	cell line; luminal epithelial, ERBB2 positive
svcc74.2	SW872	cell line; liposacroma derived cell line
svcc71.2	T47D	cell line; luminal epithelial, estrogen receptor positive
svcc38.2	184A1	cell line; basal epithelial, immortal derivative of 184Aa
svcc17.2	184Aa	cell line; basal epithelial, a second HMEC isolate unrelated to HMEC-C
svcc40.2	184B5	cell line; basal epithelial, immortal derivative of 184Aa